Revolution Medicines' RAS Inhibitor Cleared in Five Weeks & Spyre's TL1A Antibody Misses in Rheumatoid Arthritis

Revolution Medicines filed a pancreatic cancer drug on July 22nd and had it approved five weeks later — by a company that has never sold a drug in its life.

Plus Spyre's TL1A antibody misses in rheumatoid arthritis and takes a billion dollars of market value down with it, and Biohaven sells its most advanced asset to stay solvent. Let's get into it.

Welcome to The Pharma Closeout for Wednesday, August 26th. I'm Alex Mercer.

And I'm Maya Patel.

Five weeks. That's the whole regulatory arc — submission to approval — for daraxonrasib, now branded Rasonque. We flagged this one under the radar on the ninth. It has landed, and it landed faster than anyone had it modeled. Approved for previously treated metastatic pancreatic adenocarcinoma, in patients who aren't eligible for multiagent therapy.

The speed wasn't goodwill, it was a mechanism. Fierce reported it went through the Commissioner's National Priority Voucher program — the pathway Makary set up before he stepped down. So the precedent being set today isn't an oncology precedent. It's that a voucher can compress a review from months to weeks.

Which makes the next question who gets one.

And the data is why this one did. Median overall survival was longer than with chemotherapy in the Phase 3. Revolution's chief development officer told BioPharma Dive in May that was the first time any pancreatic cancer patients had lived a median of more than a year on an experimental drug in a trial. That's what ASCO stood up for.

Here's where I want to push, though. The approval is the setup. The story is that Revolution Medicines has never commercialized anything — not one product, ever — and RBC is modeling roughly eleven and a half billion dollars in peak annual sales. That's a standing start into an extremely steep curve, and history says that's exactly where good drugs get squandered.

I'd reframe the risk rather than concede it. They haven't been standing still — more than two thousand people had already received this drug under compassionate use as of the beginning of this month. Two thousand patients on therapy, prescribers who've handled it, sites that know the dosing. That's not launching from zero. That's launching from a running start you can't see in the org chart.

Then what breaks?

The label. Second-line only, and only for patients not eligible for multiagent therapy. That is a carved-out slice of an already brutal disease. Every dollar of that peak number assumes movement into first-line and adjuvant — those trials are running, they haven't read out. The label they hold today does not support the number the street is using.

So the disagreement isn't commercial capability at all. It's that the market has priced a label that doesn't exist yet.

That's the sharper version, yes.

Then the competitive read is a timing read. If you're running commercial strategy in oncology, the thing to take from today is not the KRAS science — it's that a voucher just collapsed a review to five weeks. Every launch-readiness plan you built on a ten-month clock could be wrong by two quarters. Your manufacturing, your field build, your payer conversations all have to move left.

And watch the second act, because it's already visible. FDA granted breakthrough designation in previously treated non-small cell lung cancer with KRAS mutations other than G12C. Pancreatic proved the mechanism works. Lung decides whether this is a franchise or a platform — and a stock that's run more than fivefold in a year has already voted on that question without the data.

Shifting to the deal side, and this one has a very different mood. Biohaven is handing global rights to opakalim — its late-stage focal epilepsy drug — to South Korea's SK Biopharmaceuticals. Up to seven hundred and ninety-five million dollars, per Endpoints, with three hundred and fifty million of that upfront.

And they sold ahead of the readout. Rise3 topline lands before the end of the year. You don't do that from strength.

RBC's Leonid Timashev said exactly that — called it surprising, given this was the company's most mature asset, and noted that doing it now, with SK rather than a larger partner, doesn't suggest it was being valued at a premium.

Leerink's Marc Goodman gave the generous read — that Biohaven sees itself as an investor rather than an epilepsy company. I'd put it differently. This is a company that has absorbed a depression drug failure, a rejection on Vyglxia, and a miss in spinal muscular atrophy, converting its best remaining asset into non-dilutive capital before a binary event it might not have survived.

Which is the implication worth carrying out of this. In a year where everyone's tracking capital flowing from China into US biotech, a US company just sold worldwide rights to a Korean partner to fund itself. If you're modelling licensing flows, the arrow doesn't only point one direction anymore.

On the regulatory side, the story is what that voucher is doing to the shape of the calendar. Rasonque cleared more than half a year before its statutory deadline — that's the FDA's own Oncology Center of Excellence director on the record, calling the results unprecedented in an area of high unmet need.

That's an unusual thing for the agency to say in its own release.

It is. But here's what I'd actually flag for anyone building submission strategy. The agency is running that pathway while reorganizing above it. CNBC reported the FDA is weighing new deputy commissioner posts — one for drugs, one for technology and AI — reporting to the commissioner nominee, Heidi Overton, who has not been through the Senate yet.

A compressed pathway and an unsettled org chart.

At the same time. And priority pathways only hold when review capacity is stable. So if you're building a filing plan for next year on the assumption that a five-week precedent is repeatable, you're underwriting an agency structure that doesn't have permanent leadership. Build the fast case. Don't build only the fast case — because the downside scenario isn't a slower review, it's a launch org sitting idle for two quarters you already paid for.

Before we look ahead — Spyre Therapeutics. Its anti-TL1A antibody SPY072 fell short in Phase 2 in rheumatoid arthritis. Shares tumbled thirteen percent, erasing more than a billion dollars in market value in a single session.

And the shape of the miss matters more than the miss. Two doses against placebo, twelve weeks. The low dose hit statistical significance on disease activity. The high dose missed its primary objective entirely.

High dose underperforming low dose — that's the part that should worry people.

That's the tell. When dose-response inverts, you don't have a potency problem you can solve by pushing harder. Spyre effectively conceded it by declining to prioritize monotherapy here and pivoting to combinations.

Which reads to me like protecting the platform story after the asset failed the test.

Partly — but Leerink's Thomas Smith called it disappointing while holding that the core IBD combination thesis is intact, and that's defensible. Merck, Roche and Sanofi all chose ulcerative colitis and Crohn's as their lead TL1A indications and are in Phase 3 there. Here's the thread nobody's pulling: Merck started Phase 2b trials last year in the same rheumatic indications Spyre just failed in. Spyre's psoriatic arthritis and axial spondyloarthritis data land in the fourth quarter. If those miss too, this stops being a Spyre story — it means TL1A is a bowel mechanism, and the rheumatology expansion the whole sector underwrote was never there to buy.

Looking ahead — those fourth-quarter Spyre readouts are now the referendum on the mechanism, not on one company. And Biohaven's Rise3 topline before year-end tells us whether SK bought a bargain or a warning.

I'd add Revolution's lung Phase 3, and one thing underneath it. European regulators are running Rasonque under a phased review. If that clears fast too, compressed timelines stop being an American anomaly and start being the planning assumption on both sides of the Atlantic — which changes when you staff a launch, not just how you file.

The thing I'll be sitting with tonight is that survival curve. Thirteen months against six and a half, in a disease where the number hasn't moved in a decade. Everything else we said today sits downstream of that.

And that is your Pharma Closeout for Wednesday, August 26th — Revolution Medicines clearing a five-week review for Rasonque, Spyre's TL1A miss taking a billion dollars off the table, and Biohaven trading opakalim to SK Biopharmaceuticals for the cash to keep going. Three companies, three completely different relationships with the clock. Follow the show on Apple Podcasts, Spotify, or wherever you listen — a quick rating or share helps other listeners find us. Tomorrow's briefing lands on its own.